Compare GSK plc (GSK) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Harmony Gold Mining Co. — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B). The key difference: GSK plc is far larger — about 9.2× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays the higher dividend (4.63%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Harmony Gold Mining Co. for 45 Days on average.
| GSK | HMY | |
|---|---|---|
Market Cap | $91.88B | $10.02B |
Volume | 7,730,529 | 3,643,683 |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $26.04 |
52-Week Low | $43.24 | $13.32 |
Typical Hold Time | 93 Days | 45 Days |
Enterprise Value | $111.88B | $10.07B |
Dividend Yield | 3.9% | 4.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Harmony Gold Mining (HMY) trades at $16.88, up 2.37% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Fundamentally, the company shows strong profitability with a 29.57% net income margin and robust revenue growth, climbing from $42.6B in 2022 to $73.9B in 2025. Recent earnings have been mixed, with two beats and two misses in the last four quarters. Analyst sentiment is cautious, with a consensus leaning heavily toward Hold.
The outlook for HMY is balanced; its low P/E of 6.02 and expansion into copper production offer value, but bearish technicals and high hold ratings suggest near-term volatility. Key risks include execution of growth projects and commodity price fluctuations, while institutional interest remains a supportive factor.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
